SSC Children 2026 — Part 3: Vasoactive Medications & Ventilation

This section covers vasoactive medication management and ventilation strategies in pediatric sepsis and septic shock, including the timing of vasoactive initiation relative to fluid resuscitation, first-line vasoactive agent selection, peripheral venous access for vasoactive infusions, adjunctive vasopressor and inotropic agents, intubation decisions, choice of induction agents, and oxygen saturation targets. These recommendations apply to pediatric patients from 37 weeks gestational age at birth through 18 years of age.

1. Vasoactive Medication Timing

Recommendation 30 — Vasoactive Initiation Relative to Fluid Volume

There is insufficient evidence to recommend initiating vasoactive medications either before or after 40 mL/kg of bolus fluid therapy in children with septic shock.

No recommendation (insufficient evidence)

Change from 2020: New recommendation.

Rationale: Three small RCTs were identified that examined the timing of vasoactive initiation relative to fluid volume administered. Pooled analysis demonstrated no mortality difference (RR 0.62; 95% CI 0.23-1.69). The sample sizes were insufficient to draw definitive conclusions.

“In our practice”: 63% of panel members reported that they often or sometimes initiate vasoactive medications before completing 40 mL/kg of fluid bolus therapy, reflecting a trend toward earlier vasoactive support in clinical practice. This practice variation underscores the need for larger RCTs to inform the optimal timing of vasoactive initiation relative to fluid resuscitation volume.

2. First-Line Vasoactive Agent Selection

Recommendation 31 — Epinephrine vs. Norepinephrine

There is insufficient evidence to recommend the preferential use of either epinephrine or norepinephrine as first-line vasoactive therapy in children with septic shock.

No recommendation (insufficient evidence)

Change from 2020: Updated.

Rationale: One RCT of 67 children compared epinephrine to norepinephrine combined with dobutamine and found no significant differences in hemodynamic outcomes or mortality. A propensity-matched analysis of 231 septic shock episodes showed no difference in major adverse kidney events, but epinephrine was associated with greater 30-day mortality (3.7% vs. 0%), though this finding requires cautious interpretation given the observational design and small sample.

“In our practice”: 57% of panel members commonly use epinephrine as their first-line vasoactive agent, while 43% commonly use norepinephrine. This near-even split reflects the absence of definitive evidence favoring either agent. Agent selection may reasonably be guided by the predominant hemodynamic phenotype — epinephrine for cold shock with myocardial dysfunction, norepinephrine for warm vasodilatory shock — though this approach has not been validated in RCTs.

3. Route of Vasoactive Administration

Recommendation 32 — Peripheral Venous Access for Vasoactives

For children with septic shock, we suggest initiating vasoactive medications through peripheral venous access over delaying initiation until central venous access is obtained.

Conditional recommendation, very low certainty evidence

Change from 2020: Updated.

Rationale: A meta-analysis of 6 new observational studies enrolling 709 children demonstrated a reduced risk of death with vasoactive initiation through peripheral access compared with delayed initiation pending central venous catheterization (RR 0.45; 95% CI 0.3-0.67). The risk of extravasation injury with peripheral vasoactive infusion was low (2.5%; 95% CI 1.69-4.2%).

The benefit of early vasoactive support outweighs the small risk of local tissue injury from extravasation when central venous access is not immediately available. Peripheral vasoactive infusions should be administered through a well-functioning peripheral IV, ideally in a proximal vein, with close monitoring for signs of extravasation. Central venous access should be established as soon as feasible, but the process should not delay vasoactive initiation.

4. Adjunctive Vasoactive Agents

Recommendation 33 — Vasopressin for High-Dose Catecholamine Requirements

For children with septic shock who require high-dose catecholamines, we suggest either adding vasopressin or further titrating catecholamines.

Conditional recommendation, low certainty evidence

Change from 2020: No change (carried over).

Rationale: Vasopressin acts through V1 receptors to cause vasoconstriction through a catecholamine-independent mechanism and may be effective when catecholamine resistance develops. The addition of vasopressin to high-dose catecholamine infusions may allow reduction in catecholamine doses and their associated adverse effects (tachyarrhythmias, excessive metabolic stimulation). However, evidence for vasopressin in pediatric septic shock remains limited, and either adding vasopressin or continuing to titrate catecholamines is a reasonable approach.

Recommendation 34 — Inodilators for Cardiac Dysfunction

For children with septic shock and cardiac dysfunction despite initial vasoactive therapy, there is insufficient evidence to recommend the addition of an inodilator.

No recommendation (insufficient evidence)

Change from 2020: No change (carried over).

Rationale: Inodilators (milrinone, levosimendan) may improve cardiac output and reduce afterload in children with myocardial dysfunction complicating septic shock. However, the evidence base is insufficient to formulate a recommendation. The vasodilatory effects of these agents may worsen hypotension, particularly in the setting of concomitant vasodilatory shock, and their use requires careful hemodynamic monitoring.

Recommendation 35 — Angiotensin II for Vasodilatory Shock

For children with persistent vasodilatory septic shock, there is insufficient evidence to recommend co-treatment with angiotensin II.

No recommendation (insufficient evidence)

Change from 2020: New recommendation.

Rationale: Angiotensin II acts on AT1 receptors to produce vasoconstriction and has been studied as a rescue vasopressor in refractory vasodilatory shock in adults (ATHOS-3 trial). However, the three identified pediatric studies were small retrospective case series, providing insufficient evidence to support a recommendation. The safety, dosing, and efficacy of angiotensin II in children with septic shock remain undefined.

Recommendation 36 — Methylene Blue for Vasodilatory Shock

For children with persistent vasodilatory septic shock, there is insufficient evidence to recommend co-treatment with methylene blue.

No recommendation (insufficient evidence)

Change from 2020: New recommendation.

Rationale: Methylene blue inhibits nitric oxide synthase and guanylate cyclase, potentially counteracting the pathological vasodilation mediated by excessive nitric oxide production in septic shock. One single-center RCT of 30 neonates with septic shock found no mortality difference with methylene blue administration. The evidence is insufficient to support its routine use, and methylene blue carries risks including methemoglobinemia and serotonin toxicity in patients receiving serotonergic medications.

5. Airway & Ventilation Management

Recommendation 37 — Intubation in Fluid-Refractory Shock

For children with fluid-refractory, catecholamine-resistant septic shock in the absence of respiratory failure, there is insufficient evidence to recommend intubation and mechanical ventilation.

No recommendation (insufficient evidence)

Change from 2020: No change (carried over).

Rationale: Intubation and mechanical ventilation reduce the work of breathing and may decrease oxygen consumption, potentially redirecting cardiac output to other vital organs. However, the induction of anesthesia and positive pressure ventilation can precipitate hemodynamic collapse in patients with compromised cardiovascular function. In the absence of overt respiratory failure, the decision to intubate should be individualized based on the trajectory of hemodynamic compromise, the anticipated need for procedures (e.g., central line placement), and the clinical team’s assessment of the risk-benefit balance.

Recommendation 38 — Etomidate Avoidance

For children with septic shock who require intubation, we suggest against using etomidate for induction.

Conditional recommendation, low certainty evidence

Change from 2020: No change (carried over).

Rationale: Etomidate causes reversible inhibition of 11-beta-hydroxylase, suppressing adrenal cortisol synthesis for up to 24-72 hours after a single dose. In the context of septic shock, where the hypothalamic-pituitary-adrenal axis is already stressed, even transient adrenal suppression may worsen hemodynamic instability. Alternative induction agents — including ketamine, which has sympathomimetic properties and preserves hemodynamic stability — should be considered.

Recommendation 39 — Conservative Oxygen Saturation Targets

For children with sepsis or septic shock requiring supplemental oxygen, we suggest titrating to a conservative SpO2 target of 88-92% rather than a more liberal target of SpO2 greater than 94%.

Conditional recommendation, moderate certainty evidence

Change from 2020: New recommendation.

Rationale: Four RCTs evaluating liberal versus conservative SpO2 targets in critically ill children were identified. Pooled analysis demonstrated that conservative oxygen targets were associated with shorter hospital length of stay (mean difference 0.39 days; 95% CI 0.11-0.66), reduced duration of mechanical ventilation, and fewer adverse effects compared with liberal targets.

The OxyPICU trial specifically demonstrated that targeting SpO2 88-92% led to more days alive without organ support at day 30 compared with an SpO2 target greater than 94%.¹ These findings align with adult critical care data and the physiological understanding that hyperoxia may cause oxidative stress, atelectasis, and vasoconstriction.

Remarks: This recommendation applies to children receiving supplemental oxygen who have achieved hemodynamic stability. It does not apply to specific conditions where higher oxygen targets may be warranted, such as carbon monoxide poisoning, severe traumatic brain injury, or acute anemia with ongoing hemorrhage. Patients with congenital cyanotic heart disease may have different baseline oxygen saturations that should guide target selection.

Quick Reference: Vasoactive Medications & Ventilation

VASOACTIVE MEDICATIONS & VENTILATION — AT A GLANCE (Recs 30-39)

1. VASOACTIVE TIMING & SELECTION
   —  Initiate vasoactives before or after 40 mL/kg fluid          [Insufficient evidence]
      ("In our practice": 63% often/sometimes start before 40 mL/kg)
   —  Epinephrine vs norepinephrine as first-line                   [Insufficient evidence]
      ("In our practice": 57% epinephrine, 43% norepinephrine)

2. ROUTE OF ADMINISTRATION
   ✓  Start vasoactives via peripheral IV over delaying for         [Conditional, very low CoE]
      central access
      • Reduced mortality risk (RR 0.45; 95% CI 0.3-0.67)
      • Low extravasation risk (2.5%)

3. ADJUNCTIVE VASOACTIVE AGENTS
   ✓  High-dose catecholamines → add vasopressin OR further         [Conditional, low CoE]
      titrate catecholamines
   —  Inodilator for cardiac dysfunction on vasoactives             [Insufficient evidence]
   —  Angiotensin II for persistent vasodilatory shock              [Insufficient evidence]
   —  Methylene blue for persistent vasodilatory shock              [Insufficient evidence]

4. AIRWAY & VENTILATION
   —  Intubation for fluid-refractory, catecholamine-resistant      [Insufficient evidence]
      shock (without respiratory failure)
   ✓  Avoid etomidate for intubation in septic shock                [Conditional, low CoE]
   ✓  Target SpO2 88-92% over SpO2 >94%                            [Conditional, moderate CoE]
      • Shorter hospital LOS, shorter MV duration
      • OxyPICU: more organ-support-free days at day 30

KEY: ✓✓ = Strong recommendation ("we recommend")
     ✓  = Conditional recommendation ("we suggest")
     GPS = Good practice statement
     —  = No recommendation / insufficient evidence
     CoE = Certainty of evidence

References